Home/Pipeline/NX210c

NX210c

Amyotrophic Lateral Sclerosis (ALS)

Phase 2Active

Key Facts

Indication

Amyotrophic Lateral Sclerosis (ALS)

Phase

Phase 2

Status

Active

Company

Axoltis Pharma

About Axoltis Pharma

Axoltis Pharma is a clinical-stage biotech company pioneering CNS regeneration therapies. Its lead asset, NX210c, is a therapeutic peptide with a dual mechanism of action targeting blood-brain barrier integrity and neuronal protection/function. The company has raised €18M, completed a Phase 1b trial, and is currently conducting a Phase 2 trial in Amyotrophic Lateral Sclerosis (ALS). Axoltis aims to address significant unmet needs in severe neurological disorders through its innovative peptide-based approach.

View full company profile

Therapeutic Areas

Neurology Neurodegenerative Diseases

Other Amyotrophic Lateral Sclerosis (ALS) Drugs

Drug	Company	Phase	Status
NPT520-34	Neuropore Therapies	Pre-clinical/Phase 1	Partnered (Biogen), Active
NUZ-001	Neurizon Therapeutics	Phase 2/3 (Platform Trial)	Active
CNM-Au8	Clene	Phase 2/3	Active
Masitinib	AB Science	Phase 3	Active
Undisclosed Program	Zhimeng Biopharma	Clinical	Active
SLS-005	Seelos Therapeutics	Platform Trial	Active (HEALEY ALS Platform Trial – Regimen E)
PMN442	ProMIS Neurosciences	Preclinical	Active
nAV-101	nVector	Pre-clinical	Active
ALTA-808	Alteron Therapeutics	Preclinical	IND-enabling studies launching
GM6	Genervon Biopharmaceuticals	Phase 2	Active
Lou Gehrig’s disease	Genclis	Discovery	Active
Treg-directed therapy for ALS	Iltoo Pharma	Pre-clinical	Active